Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. 2002

Stefano Aquaro, and Patrizia Bagnarelli, and Tania Guenci, and Andrea De Luca, and Massimo Clementi, and Emanuela Balestra, and Raffaele Caliò, and Carlo-Federico Perno
Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy. aquaro@uniroma2.it

The role of macrophages in the pathogenesis and progression of human immunodeficiency virus (HIV)-related infection is substantiated by in vitro and in vivo evidence. The unique ability to survive HIV infection and produce viral particles for long periods is postulated. Detailed studies of this phenomenon are lacking. The dynamics of HIV-1 replication and cumulative virus production was studied in long-term cultures of macrophages in the presence or in the absence of antiviral drugs. Multiply spliced and unspliced HIV-RNA production was assessed by quantitative PCR, and the number of infected cells was monitored by FACS analysis. Cumulative HIV-1 production was determined by a trapezoidal equation, including such parameters as times of collection and experimental values of genomic-RNA and p24 gag antigen. Unspliced and multiply spliced HIV-RNA increased linearly after macrophage infection; reached levels of 1.5 x 10(8) and 2.8 x 10(5) copies/10(5) cells, respectively, at day 10; and then remained stable throughout the course of the experiment. Cumulative production of genomic-RNA and p24 gag antigen was 10(10) copies/10(6) cells and 10(7) pg/10(6) cells, respectively, with an average of >200 virus particles produced daily by each macrophage. AZT decreased the cumulative production of both genomic-RNA and p24 gag antigen down to 2.5 x 10(9) copies and 1.1 x 10(6) pg/10(6) cells (73.8% and 88.9% inhibition, respectively) up to day 50 without virus breakthrough. Ritonavir had a limited, but consistent, efficacy on the release of mature virus proteins (about 40% inhibition), but not on HIV-RNA production. In conclusion, the long-term dynamics and the high cumulative virus production that characterize HIV-1 infection of macrophages underscore the peculiar role of these cells as a persistently infected reservoir of HIV.

UI MeSH Term Description Entries
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D014158 Transcription, Genetic The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION. Genetic Transcription
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D019438 Ritonavir An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A. ABT 538,ABT-538,Norvir,ABT538

Related Publications

Stefano Aquaro, and Patrizia Bagnarelli, and Tania Guenci, and Andrea De Luca, and Massimo Clementi, and Emanuela Balestra, and Raffaele Caliò, and Carlo-Federico Perno
April 1992, The Journal of general virology,
Stefano Aquaro, and Patrizia Bagnarelli, and Tania Guenci, and Andrea De Luca, and Massimo Clementi, and Emanuela Balestra, and Raffaele Caliò, and Carlo-Federico Perno
February 2004, Antiviral research,
Stefano Aquaro, and Patrizia Bagnarelli, and Tania Guenci, and Andrea De Luca, and Massimo Clementi, and Emanuela Balestra, and Raffaele Caliò, and Carlo-Federico Perno
April 1993, AIDS research and human retroviruses,
Stefano Aquaro, and Patrizia Bagnarelli, and Tania Guenci, and Andrea De Luca, and Massimo Clementi, and Emanuela Balestra, and Raffaele Caliò, and Carlo-Federico Perno
September 2000, Journal of leukocyte biology,
Stefano Aquaro, and Patrizia Bagnarelli, and Tania Guenci, and Andrea De Luca, and Massimo Clementi, and Emanuela Balestra, and Raffaele Caliò, and Carlo-Federico Perno
January 1997, Archives of internal medicine,
Stefano Aquaro, and Patrizia Bagnarelli, and Tania Guenci, and Andrea De Luca, and Massimo Clementi, and Emanuela Balestra, and Raffaele Caliò, and Carlo-Federico Perno
October 1992, The Journal of infectious diseases,
Stefano Aquaro, and Patrizia Bagnarelli, and Tania Guenci, and Andrea De Luca, and Massimo Clementi, and Emanuela Balestra, and Raffaele Caliò, and Carlo-Federico Perno
May 1999, The Journal of infectious diseases,
Stefano Aquaro, and Patrizia Bagnarelli, and Tania Guenci, and Andrea De Luca, and Massimo Clementi, and Emanuela Balestra, and Raffaele Caliò, and Carlo-Federico Perno
July 1991, The Journal of pediatrics,
Stefano Aquaro, and Patrizia Bagnarelli, and Tania Guenci, and Andrea De Luca, and Massimo Clementi, and Emanuela Balestra, and Raffaele Caliò, and Carlo-Federico Perno
August 1991, AIDS research and human retroviruses,
Stefano Aquaro, and Patrizia Bagnarelli, and Tania Guenci, and Andrea De Luca, and Massimo Clementi, and Emanuela Balestra, and Raffaele Caliò, and Carlo-Federico Perno
January 2016, Transplantation,
Copied contents to your clipboard!